

# Index

- A**
- AA. *See* Aplastic anemia
- ABL1*, 347, 368–369
- ABL2*, 369
- ABT-199, 368
- ABT-731, 181
- ACIN1*, 374
- Acute lymphocytic leukemia (ALL). *See also* B-progenitor acute lymphoblastic leukemia; T-cell acute lymphoblastic leukemia
- epidemiology
    - adult, 32–33
    - pediatric, 29–30
- Acute megakaryoblastic leukemia (AMKL)
- children without Down syndrome, 326–329
  - Down syndrome association
    - clinical and biological features, 324–325
    - GATA1*
      - cooperation with trisomy genes, 323–324
      - mutations, 323
    - genetic susceptibility, 321–322
    - transforming mutation acquisition, 325–326
  - overview, 319–320
  - RNA-binding proteins, 153
- Acute myeloid leukemia (AML)
- chromosomal abnormalities
    - core binding factor rearrangements, 296–297
    - KMT2A* rearrangements, 298–299
    - rare translocations, 299–300
  - clonal hematopoiesis, 75
  - epidemiology
    - adult, 31–32
    - pediatric, 29–31
  - epigenetics
    - cytosine methylation profiles, 115–117
    - gene mutations
      - ASXL1*, 120–121, 306
      - BCOR*, 306–307
      - BCORL1*, 306–307
      - cohesin, 307
      - DNMT3A*, 117, 304–305
      - EZH2*, 120
      - IDH1*, 120, 305–306
      - IDH2*, 120, 305–306
      - LUC7L2*, 307
      - PRPF8*, 307
      - SF3B1*, 307
      - SRSF2*, 307
      - SUZ12*, 120
      - TET2*, 117, 119, 121, 305
      - U2AF1*, 307
      - U2AF2*, 307
      - ZRSR2*, 307
- therapeutic targeting
  - combination therapy, 123–124
  - histone epigenetic mechanisms, 121, 123
  - specific epigenetic mechanisms, 121
- induced pluripotent stem cell models, 257–259
- leukemia stem cell studies. *See* Leukemia stem cell model
- mouse models. *See* Mouse models
- pathophysiology, 295–296
- recurrent mutations
  - CEBPA*, 301–302
  - GATA2*, 302
  - NPM1*, 300–301
  - RUNX1*, 301
- signal transduction mutations
  - CBL*, 303
  - FLT3*, 302
  - KIT*, 302–303
  - KRAS*, 303
  - NF1*, 303–304
  - NRAS*, 303
  - PTPN11*, 303
- therapeutic targeting
  - CD123, 91–92
  - CD33, 90
  - FLT3, 90–91
  - limitations, 90
  - prospective leukemia stem cell targets.
    - See* Leukemia stem cell
- tumor suppressor gene mutations
  - PHF6*, 308
  - TP53*, 307–308
  - WT1*, 308
- ADI-PEG20, 182
- Adult T-cell leukemia/lymphoma (ATLL)
- clinical presentation, 473–474
  - genetics, 474
  - pathogenesis, 473

## Index

- AF10*, 298  
*AF4*, 298  
*AF9*, 298, 303  
Age-related clonal hematopoiesis (ARCH), 11, 13, 73  
*AICDA*, 49  
*AITL*. *See* Angioimmunoblastic T-cell lymphoma  
*AKT*, 346  
*ALCL*. *See* Anaplastic large cell lymphoma  
Alisertib, 329  
*ALK*, 431  
*ALK*, 55–56, 473  
*ALL*. *See* Acute lymphocytic leukemia  
*AMKL*. *See* Acute megakaryoblastic leukemia  
*AML*. *See* Acute myeloid leukemia  
*AML1*, 303  
*AMPK*, 7  
Anaplastic large cell lymphoma (ALCL)  
    clinical features, 472  
    genetics, 472–473  
    genetics, 55–56, 472–473  
    overview, 187  
Angioimmunoblastic T-cell lymphoma (AITL)  
    epidemiology, 469  
    genetics, 57 469–471  
*APC*, 326, 471  
Aplastic anemia (AA), 74  
*APOBEC*, 119  
*ARAF*, 425  
*ARCH*. *See* Age-related clonal hematopoiesis  
*ARF*, 340  
*ARHGEF1*, 240  
*ARID1A*, 51, 54, 476  
*ARID1B*, 475  
*ARID1B*, 471  
*ARID2*, 283  
*ARID2*, 471  
*ARID5B*, 476  
*ASCT2*, 181  
*ASNS*, 181  
*ASS1*, 182  
*ASXL1*, 70, 74, 120–121, 260, 280–281, 302, 306  
*ATLL*. *See* Adult T-cell leukemia/lymphoma  
*ATM*, 49, 243, 451, 454  
*ATR*, 128  
*AURKA*, 329
- B**
- Bach2*, 206  
B-ALL. *See* B-progenitor acute lymphoblastic leukemia  
*BAP1*, 306  
*BAX*, 186, 456  
*BCAT1*, 159, 184  
B-cell, development, 226–227, 448–449  
B-cell lymphoma. *See also specific lymphomas*  
    classification, 448, 451  
    genetics, 450–451  
    germinal center B-cell-derived lymphomas, 451–452  
    lymphomagenesis, 448  
    post-germinal center and marginal zone B-cell-derived lymphomas, 452–453  
    pre-germinal center B-cell-derived lymphomas, 451  
B-cell maturation antigen (BCMA), 494–497  
*BCL1*. *See* *CCND1*  
*BCL2*, 49, 152, 183, 185, 368, 396, 399  
*BCL2*, 52, 54, 162, 234–236, 239, 374, 448, 452  
*BCL6*, 128, 236–237, 239, 242, 306  
*BCL6*, 52, 54, 374, 452  
*BCL11B*, 342, 344  
*BCMA*. *See* B-cell maturation antigen  
*BCOR*, 74, 306–307  
*BCORL1*, 74, 306–307  
*BCR*, 368–369  
*BHLH1*, 341  
Bioenergetics. *See* Metabolism, leukemia/lymphoma  
*BIRC3*, 389  
BiTEs, 495–497  
*BL*. *See* Burkitt lymphoma  
*BLCL2A1*, 186  
*BLIMP1*, 241  
*BMI1*, 152, 161  
Bortezomib, 478, 489  
B-progenitor acute lymphoblastic leukemia (B-ALL)  
    chromosomal alterations  
        gross abnormalities, 364, 367  
        translocations, 367–368  
    inherited variants, 375–376  
    microenvironment, 377  
    mixed phenotype ALL, 374–375  
    overview, 363–364  
    prospects for study, 377–378  
    relapse, 376–377  
    subtypes  
        DUX4-rearranged ALL, 371  
        ETV6-RUNX1-like ALL, 369  
        *IGH* rearrangements, 374  
        IKZF1 N159Y, 372, 374  
        *MEF2D* rearrangement, 371  
        novel subtypes, 368–372  
        *NUTM1* rearrangements, 374  
        PAX5-driven subtypes, 372  
        Ph-like ALL, 369  
        prevalence and prognosis, 365–366  
        *ZNF384* rearrangement, 371–372  
*BRAF*, 425, 439, 492  
*BRAF*, 51, 53, 59, 421–423, 430–433, 437–440  
*BRD4*, 281  
*BRD4*, 374

- BRD9*, 374
- Brentuximab, 456
- BTK, 49, 403, 456
- BTK*, 50
- BTLLA*, 364
- Burkitt lymphoma (BL)
  - genetics, 54
  - mouse models, 232–233
  
- C**
- CALR*, 257, 276
- CARD11*, 56, 457, 476
- Carfilzomib, 488
- CBCL. *See* Primary cutaneous B-cell lymphoma
- CBFA2T3, 328–329
- CBFB*, 296–297
- CBL, 284
- CBL*, 70, 284–285, 303
- CCL3, 393
- CCL4, 393
- CCND1*, 50, 52, 229, 451
- CCND2*, 341
- CCND3*, 51, 54, 233, 338, 340, 439
- CCR4, 474, 479
- CCR4*, 57
- CCR7, 474
- CCUS. *See* Clonal cytopenia of undetermined significance
  
- CD3, 348
- CD7, 348
- CD19, 458
- CD200*, 364
- CD23, 395
- CD28*, 471, 474
- CD30, 480
- CD31, 393
- CD33, 90
- CD38, 392–393, 395, 491, 493, 497
- CD47, 479
- CD58*, 474
- CD79B*, 452–453
- CD123, 91–92
- CDK4, 232
- CDK4*, 338
- CDK6*, 338
- CDKN1A*, 237
- CDKN1B*, 237, 340, 476
- CDKN2A*, 56, 337, 340, 364, 368, 375
- CDKN2B*, 364, 368, 375
- CDKN2D*, 338
- CDR*, 242
- C/EBP, 159–160
- CEBPA*, 301–302
  
- CFS1R*, 371
- CH. *See* Clonal hematopoiesis
- CHAF1B*, 322
- CHD8*, 471
- CHEK1*, 128
- CHIP, 276
- Chronic lymphocytic leukemia (CLL)
  - B-cell surface receptors
    - B-cell receptor signaling, 390–392
    - chemokine receptors, 392
    - microenvironmental signals associated with clonal expansion, 392–393
  - combinatorial indices in management, 396
  - diagnosis, 395
  - epidemiology, 386
  - genetics
    - noninherited recurrent mutations, 388–390
    - susceptibility genes, 386, 388
  - monoclonal B-cell lymphocytosis, 393–394
  - normal cell equivalents, 394–395
  - overview, 385–386
  - predictive markers in therapy, 395–396
  - prognostic markers, 395
  - progression
    - aggressive clonal variant promoters, 399
    - cell growth rate role, 400
    - clonal evolution, 400
    - Richter's transformation, 400, 402–403
  - risk factors, 386
  - treatment
    - anti-apoptotic protein targeting, 399
    - chemoimmunotherapy, 398
    - initial therapy, 396–397
    - monoclonal antibodies, 398
    - pathway inhibitors, 398–399
    - progression targeting, 403
    - refractory disease, 402–403
    - relapsed disease, 402–403
- Chronic Lymphocytic Leukemia International Prognostic Index (CLL-IPI), 396
- Chronic lymphocytic leukemia/small cell lymphoma (CLL/SCL)
  - epidemiology, 33–34
  - genetics, 48–50
  - mouse models, 242–243
- Chronic myeloid leukemia (CML)
  - epidemiology, 33
  - induced pluripotent stem cell models, 255–256
- CLL. *See* Chronic lymphocytic leukemia
- CLL/SCL. *See* Chronic lymphocytic leukemia/small cell lymphoma
- CLL-1, acute myeloid leukemia therapeutic targeting, 101–102

## Index

- CLL-IPI. *See* Chronic Lymphocytic Leukemia  
International Prognostic Index
- Clonal cytopenia of undetermined significance  
(CCUS), 73–74
- Clonal hematopoiesis (CH)  
aplastic anemia, 74  
bystander clonal hematopoiesis, 75–76  
clonal cytopenia of undetermined significance,  
73–74  
founder clonal hematopoiesis and leukemia  
progression, 74–75  
genetic susceptibility, 77  
hematologic malignancy risk, 71  
idiopathic cytopenia of undetermined significance,  
73–74  
interventions  
follow-up, 78  
inflammation inhibition, 78  
metformin, 78  
mutation targeting, 77  
preclinical studies, 77  
vitamin C, 77–78  
multiple myeloma outcomes, 76  
mutation landscape, 70–71  
overview, 69–70  
prospects for study, 78–79  
solid tumor outcomes, 76  
technical definition, 71–73
- CML. *See* Chronic myeloid leukemia
- CNOT3*, 348
- Cohesin, 214, 255, 307
- CPI-613, 180
- CREBBP*, 234–237  
*CREBBP*, 52, 53, 128–130, 364, 452, 471
- CRISPR–Cas9, 204–205, 244, 255, 258, 460
- Crizotinib, 479
- CRLF2*, 367, 369, 374
- CSF1R*, 432
- CTCF, 214, 329  
*CTCF*, 329
- CTCL. *See* Cutaneous T-cell lymphoma
- CTLA4, 496
- Cutaneous T-cell lymphoma (CTCL)  
clinical presentation, 476  
genetics, 476
- CUX1*, 374
- CXCL12*, 4–5, 206, 337, 392
- CXCR4*, 206, 337, 377, 392
- CXCR4*, 453
- D**
- Daratumumab, 488
- DCAF15, 160–161
- DDX3X*, 452
- DEK*, 299
- D2HGDH, 188
- DHODH, 183
- Diffuse large B-cell lymphoma (DLBCL)  
cellular origins, 228  
epidemiology, 37–38  
epigenetics  
cytosine methylation patterning, 130  
gene mutations in epigenetic modifiers,  
128–130  
immune synapse as focal point for epigenetic  
dysregulation in lymphoma, 130  
overview, 124–128  
therapeutic targeting  
nonspecific therapies, 130, 132  
precision therapy, 132–133  
genetics, 52–54, 451–452  
heterogeneity, 460–461  
mouse models  
BCL6 dysregulation, 239  
*FBXO11* deletion, 240  
G $\alpha$ 13 pathway disruption, 240  
NF- $\kappa$ B signaling activation, 241–242  
*PRDM1/BLIMP1*, 241
- DLBCL. *See* Diffuse large B-cell lymphoma
- DLEU2*, 242
- DLEU7*, 242
- DNA methyltransferase. *See also* Epigenetics  
acute myeloid leukemia inhibitor therapy, 124  
*DNMT1*, 279  
*DNAMT3A*, 13–14, 57, 70, 74–75, 77–78, 85,  
117, 206, 210–211, 260, 279–280,  
304–305, 319, 469, 476
- DOT1L*, 298–299
- Down syndrome  
acute megakaryoblastic leukemia  
clinical and biological features, 324–325  
*GATA1*  
cooperation with trisomy genes, 323–324  
mutations, 323  
genetic susceptibility, 321–322  
transforming mutation acquisition, 325–326  
hematopoiesis disturbances, 321  
malignancy association, 320–321
- Durvalumab, 480
- DUSP22*, 56
- DUX4*, 368, 371
- DYRK1A*, 324  
*DYRK1A*, 367
- E**
- EATL. *See* Enteropathy-associated T-cell lymphoma
- EBF1*, 52, 364
- EBNA2, 187

- 4EBP1, 161–162
  - EBV. *See* Epstein–Barr virus
  - ECD. *See* Erdheim–Chester disease
  - EED, 345
  - eIF4E, 155–157, 161
  - eIF4G, 161
  - ELL, 298
  - ENL, 298
  - Enteropathy-associated T-cell lymphoma (EATL), 475
  - EP300, 52–53, 128–129
  - Epigenetics
    - acute myeloid leukemia
      - cytosine methylation profiles, 115–117
      - gene mutations
        - ASXL1, 120–121, 306
        - BCOR, 306–307
        - BCORL1, 306–307
        - cohesin, 307
        - DNMT3A, 117, 304–305
        - EZH2, 120
        - IDH1, 120, 305–306
        - IDH2, 120, 305–306
        - LUC7L2, 307
        - PRPF8, 307
        - SF3B1, 307
        - SRSF2, 307
        - SUZ12, 120
        - TET2, 117, 119, 121, 305
        - U2AF1, 307
        - U2AF2, 307
        - ZRSR2, 307
      - therapeutic targeting
        - combination therapy, 123–124
        - histone epigenetic mechanisms, 121, 123
        - specific epigenetic mechanisms, 121
    - B-cell lymphomas
      - cytosine methylation patterning, 130
      - gene mutations in epigenetic modifiers, 128–130
      - immune synapse as focal point for epigenetic dysregulation in lymphoma, 130
      - overview, 124–128
      - therapeutic targeting
        - nonspecific therapies, 130, 132
        - precision therapy, 132–133
    - epigenetic alleles, clonal evolution and therapy
      - resistance in leukemia/lymphoma, 133
    - mouse models of myeloid malignancies
      - DNA methylation pathways, 209–212
      - histone modification pathways, 212–213
    - T-cell acute lymphoblastic leukemia regulator
      - mutations
        - EED, 345
        - EZH2, 345
        - KDM6A, 345
        - overview, 344–345
        - PHF6, 345
        - SUZ12, 345
  - Epstein–Barr virus (EBV)
    - Burkitt lymphoma association, 232
    - Hodgkin’s lymphoma association, 39
    - non-Hodgkin’s lymphoma association, 37
  - ERBB3, 431
  - Erdheim–Chester disease (ECD)
    - cellular origins, 432–433
    - clinical presentation, 430
    - immunophenotypic features, 429
    - treatment, 433–435
  - ERG, 263–264, 321–322, 324–325, 367–368, 371, 375
  - ERK, isoforms, 431
  - ETO, 303
  - ETS2, 321–322, 324
  - ETV3, 432
  - ETV6, 259
  - ETV6, 336, 343, 364, 367–369, 375, 452
  - Everolimus, 478
  - EVI1, 182
  - EVII, 299–300
  - EZH2, 132, 213, 234, 236–237, 239, 282–283, 457–458
  - EZH2, 52, 56, 120, 128–129, 255, 257, 260, 281, 319, 326, 336, 345, 452
- F**
- FAS, 474
  - FASN, 182
  - Fatty acid oxidation. *See* Metabolism, leukemia/lymphoma
  - FBXO11, 240
  - FBXO11, 240
  - FBXW7, 474
  - FBXW7, 338–339, 389
  - FL. *See* Follicular lymphoma
  - FLT3, 14, 90–91, 124, 159, 178, 181
  - FLT3, 75, 205–207, 214, 302, 308, 336, 367–368, 372
  - Follicular lymphoma (FL)
    - epigenetics
      - cytosine methylation patterning, 130
      - gene mutations in epigenetic modifiers, 128–130
      - immune synapse as focal point for epigenetic dysregulation in lymphoma, 130
      - overview, 124–128
      - therapeutic targeting
        - nonspecific therapies, 130, 132
        - precision therapy, 132–133
      - genetics, 51–52, 452
      - mouse models

## Index

- Follicular lymphoma (FL) (*Continued*)  
  *BCL2* translocation, 234–235  
  histone modification genes, 235–237  
  *MEF2B*-activating mutations, 238–239  
  overview, 233–234  
  *RRAGC* mutations, 238  
  *TNFRSF14* loss, 237–238
- Follicular T-cell lymphoma (FTCL), genetics, 57
- FOXO1, 233
- FOXO3, 6
- FOXPI*, 453
- FTCL. *See* Follicular T-cell lymphoma
- FTO, 152
- G**
- G $\alpha$ 13, 240
- GATA1*, 319–326, 329
- GATA2*, 326
- GATA2*, 257, 259, 299, 302
- GATA3*, 336, 344, 375, 472, 474
- GLIS2*, 328–329
- GLOBOCAN, 26, 35
- GLUT1, 184–185
- GLUT5, 178
- Glycolysis. *See* Metabolism, leukemia/lymphoma
- GNA13*, 239–240, 452
- H**
- Hairy cell leukemia (HCL)  
  cellular origin, 437–438  
  clinical presentation, 435–437  
  genetics, 51  
  pathophysiology  
    gene expression and methylation profiling, 437  
    genomic profiling, 435  
  treatment  
    chemotherapy, 438  
    targeted therapy, 438–439  
    vemurafenib resistance mechanisms, 439
- HBZ*, 473
- HCL. *See* Hairy cell leukemia
- HDAC. *See* Histone deacetylase
- Hematopoiesis. *See also* Clonal hematopoiesis  
  age-related clonal hematopoiesis, 11, 13, 73  
  demand-based hematopoiesis  
    inflammatory signals and hematopoietic regeneration, 8–9  
  lineage bias and reprogramming during emergency hematopoiesis, 7–8  
  pathogen response, 9–10  
  resolution of emergency hematopoiesis, 10  
  Down syndrome disturbances, 321
- GATA1* role, 322–323  
  overview, 1–2
- Hematopoietic stem cell (HSC)  
  DNA damage and functional decline, 5–6  
  early function disruption in acute myeloid leukemia, 87–88  
  lineage commitment, 3–4  
  malignancy  
    dysregulated self-renewal in clonal hematopoiesis and malignancy, 11–14  
    overview, 11  
    regenerative pathway activation, 14  
  metabolism and activation, 6–7  
  multipotency, 2–3  
  niche, 4–5
- Hepatosplenic T-cell lymphoma (HSTCL), 475
- HES1, 338, 340
- HGBL. *See* High-grade B-cell lymphoma
- High-grade B-cell lymphoma (HGBL), genetics, 54–55
- HIPK2*, 257
- Histone deacetylase (HDAC)  
  *HDAC3*, 236  
  *HDAC9*, 371  
  inhibitors, 477, 480
- HIV. *See* Human immunodeficiency virus
- HL. *See* Hodgkin's lymphoma
- HLE*, 368
- HMGA2, 154
- HMG-CoA reductase, 182
- HNRNPA3*, 164
- hnRNPK, 159–160
- HNRNPR*, 164
- Hodgkin's lymphoma (HL)  
  epidemiology, 38–39  
  genetics, 55
- HOXA*, 206, 300, 336
- HOXA5*, 264
- HOXA9*, 158–159, 161, 263–264
- HOXA9*, 298, 342
- HOXA10*, 342
- HOXB*, 206, 300
- HOXD13*, 209
- Hprt*, 207
- HRAS*, 347
- HSC. *See* Hematopoietic stem cell
- HSTCL. *See* Hepatosplenic T-cell lymphoma
- HTLV-1, 473
- Human immunodeficiency virus (HIV)  
  Hodgkin's lymphoma association, 39  
  immunodeficiency-related lymphoma, 453–454  
  non-Hodgkin's lymphoma association, 36–37
- HuR, 155–156

- I**
- Ibrutinib, 456
  - ICH. *See* Indeterminate cell histiocytosis
  - ICUS. *See* Idiopathic cytopenia of undetermined significance
  - ID3, 232
  - ID3*, 54, 452
  - IDH, 186–188
  - IDH1, 13
  - IDH1*, 77, 120, 210, 212, 259, 279, 305–306
  - IDH2*, 13, 57, 77, 120, 210, 212, 259, 279, 305–306, 336, 469–470
  - Idiopathic cytopenia of undetermined significance (ICUS), 73–74
  - IGF2BP1, 157–158
  - IGF2BP2, 157
  - IGF2BP3, 157–158
  - IGFBP1, 178
  - IGFBP7, 157
  - IGH*, 369, 371, 452–563
  - IGHD*, 389–390, 394, 399
  - IGHJ*, 389–390, 394, 399
  - IGHV*, 389–389, 394, 396, 398–399
  - IGK*, 452
  - IGL*, 452
  - IKZF1, 178, 491, 493
  - IKZF1*, 364, 368–369, 372, 374–375, 377
  - IKZF3, 491, 493
  - IL1RAP, acute myeloid leukemia therapeutic targeting, 102–104
  - IL7R, 346–347
  - IL7R*, 367, 369
  - IMPDH, 183
  - Indeterminate cell histiocytosis (ICH)
    - cellular origins, 432–433
    - clinical presentation, 430
    - immunophenotypic features, 429
    - treatment, 433–435
  - Induced pluripotent stem cell (iPSC)
    - comparison to other patient-derived models, 260–261
    - CRISPR–Cas9, 255
    - developmental stage and impact on disease modeling, 262
    - genetic stability, 261–262
    - good practices, 263
    - hematopoietic specification, 253–255
    - leukemia/lymphoma models, 255–259
    - line-to-line variation, 262–263
    - overview, 251
    - prospects
      - expandable hematopoietic precursors, 263–264
      - leukemia studies, 259–260
      - three-dimensional culture, 264
      - transplantable cells, 264
      - reprogramming malignant cells, 251–253
  - INO80, 475
  - iPSC. *See* Induced pluripotent stem cell
  - IRF4*, 237, 243, 474
  - IRF4, 241
  - Isatuximab, 490
  - ITD*, 302–303, 308
  - Ixazomib, 488, 490
  - IZKF2*, 474
- J**
- JAK1, 8
  - JAK1*, 56, 369, 472, 476
  - JAK2, 14, 284, 286–287, 456
  - JAK2*, 55, 70, 74, 77, 257, 272, 276, 278, 326
  - JAK3*, 56, 369, 432, 476
  - JARID1A, 328
  - JMML. *See* Juvenile myelomonocytic leukemia
  - Juvenile myelomonocytic leukemia (JMML), induced pluripotent stem cell models, 257
  - Juvenile/adult xanthogranuloma (JXG/AXG)
    - cellular origins, 432–433
    - clinical presentation, 429
    - immunophenotypic features, 429
    - treatment, 433–435
  - JXG/AXG. *See* Juvenile/adult xanthogranuloma
- K**
- KDM5A, 328
  - KDM6A*, 345, 377, 471
  - KIT*, 302–303
  - KLF2*, 51, 435
  - KMT2A, 121, 123, 213, 328
  - KMT2A*, 298–299, 368, 374
  - KMT2C*, 451, 471
  - KMT2D*, 234–236
  - KMT2D*, 52–3, 128, 130, 452, 471
  - KRAS, 154, 492–493
  - KRAS*, 205, 207–209, 285, 303, 347, 364, 433, 439
- L**
- Langerhans cell histiocytosis (LCH)
    - cellular origins, 432–433
    - clinical presentation, 423, 428
    - history of study, 423
    - immunophenotypic features, 429
    - treatment, 433–435
  - LCH. *See* Langerhans cell histiocytosis
  - LCOR, 264
  - LDHA, 184

## Index

- LEF1*, 344  
Lenalidomide, 488, 490  
Leukemia  
  epidemiology  
    acute lymphocytic leukemia, 32–33  
    acute myeloid leukemia, 31–32  
    chronic lymphocytic leukemia/small cell lymphoma, 33–34  
    chronic myeloid leukemia, 33  
    global, 26  
    pediatric leukemia, 29–31  
    risk factors, 29  
    United States, 26–29  
  genetics. *See specific leukemias*  
Leukemia stem cell (LSC)  
  acute myeloid leukemia therapeutic targeting  
    CLL-1, 101–102  
    IL1RAP, 102–104  
    immunophenotype, 92  
    normal antigen expression, 93–97  
    prospects, 104  
    target functionality, 93  
    targeting strategy, 100  
    TIM-3, 100–101  
    timing of mutations, 93  
    unique antigens, 98–99  
  cell origin for acute myeloid leukemia  
    cytogenetics studies, 84  
    functional heterogeneity in acute myeloid leukemia organization, 89  
    gene expression studies, 85  
    hematopoietic stem cell function disruption, 87–88  
    mouse modeling of pre-leukemia, 84–85  
    sequencing studies, 85–87  
  overview of model, 83–84  
  relapse contribution, 89–90  
LIN28, 161  
LIN28A, 154–155  
LIN28B, 154–155  
LKB1, 7  
LMO1, 336, 341  
LMO2, 336, 341  
LNK, 284  
LPL. *See Lymphoplasmacytic lymphoma*  
LSC. *See Leukemia stem cell*  
LUC7L2, 257, 307  
LYL1, 336, 341  
Lymphoma  
  clinical genomics, 58–59  
  epidemiology  
    chronic lymphocytic leukemia/small cell lymphoma, 33–34  
    Hodgkin's lymphoma, 38–39  
    non-Hodgkin's lymphoma, 35–38  
    genetics. *See specific lymphomas*  
Lymphoplasmacytic lymphoma (LPL), genetics, 51  
LYN, 369
- ## M
- MAML1, 340  
Mantle cell lymphoma (MCL)  
  cellular origins, 228  
  genetics, 50, 451  
  mouse models, 229–232  
MAP2K1, 51–52, 423, 431, 435, 440  
MAP2K2, 431  
MAPK mutations. *See Erdheim–Chester disease*;  
  Hairy cell leukemia; Indeterminate cell histiocytosis; Juvenile/adult xanthogranuloma; Langerhans cell histiocytosis; Rosai–Dorfman–Destombes disease; *specific kinases*  
MAPK1, 451  
MBD4, 77  
MBL. *See Monoclonal B-cell lymphocytosis*  
MCL. *See Mantle cell lymphoma*  
MCL1, 49  
MDR, 242  
MDS, induced pluripotent stem cell models, 257–259  
MEF2B, 238–239  
MEF2B, 234, 238–239  
MEF2C, 298  
MEF2D, 368, 371  
MEIS1, 298  
MEIS1, 300  
MEITL. *See Monomorphic epitheliotropic intestinal T-cell lymphoma*  
Metabolism, leukemia/lymphoma  
  bioenergetics  
    leukemia  
      fatty acid oxidation, 180  
      glycolysis, 178–179  
      oxidative phosphorylation, 179–180  
    lymphoma  
      glycolysis, 184–185  
      oxidative phosphorylation, 185  
  biomass  
    leukemia  
      amino acids, 181–182  
      lipids, 182  
      nucleotides, 183  
    lymphoma  
      amino acids, 185–186  
      lipids, 186–187  
      nucleotides, 187



- differentiation
  - leukemia, 183–184
  - lymphoma, 188
- overview, 173–178
- prospects for study, 188–189
- Metformin, clonal hematopoiesis intervention, 78
- METTL14, 152–153
- METTL3, 152–153
- MF. *See* Mycosis fungoides
- MGUS. *See* Monoclonal gammopathy of undetermined significance
- Minimal residual disease (MRD), 364, 396
- MIR223, 341
- MKL1, 153–154, 328
- MLL, 303
- MLL1. *See* KMT2A
- MLL2, 377
- MLLT10, 342
- MM. *See* Multiple myeloma
- Monoclonal B-cell lymphocytosis (MBL), 70, 393–394
- Monoclonal gammopathy of undetermined significance (MGUS), 70–71
- Monomorphic epitheliotropic intestinal T-cell lymphoma (MEITL), 475
- Mouse models
  - leukemia stem cell model, 83–84
  - mature B-cell malignancies
    - B-cell development, 226–227
    - Burkitt lymphoma, 232–233
    - cellular origins, 227–229
    - chronic lymphocytic lymphoma/small lymphocytic lymphoma, 242–243
    - diffuse large B-cell lymphoma
      - BCL6 dysregulation, 239
      - FBXO11 deletion, 240
      - G $\alpha$ 13 pathway disruption, 240
      - NF- $\kappa$ B signaling activation, 241–242
      - PRDM1/BLIMP1, 241
    - follicular lymphoma
      - BCL2 translocation, 234–235
      - histone modification genes, 235–237
      - MEF2B-activating mutations, 238–239
      - overview, 233–234
      - RRAGC mutations, 238
      - TNFRSF14 loss, 237–238
    - mantle cell lymphoma, 229–232
    - overview, 225–226
    - prospects for study, 243–244
  - myeloid malignancies
    - cohesins, 214
    - constitutive versus conditional models, 203–204
    - CRISPR–Cas9, 204–205
    - epigenetic regulator models
      - DNA methylation pathways, 209–212
      - histone modification pathways, 212–213
    - knock-in models, 203
    - overview, 199–202
    - somatic mutation studies
      - NPM1, 205–207
      - signaling pathways, 207–209
    - spliceosome gene models, 213–214
    - TP53, 214–216
    - transgenic models, 201
    - transplantation models, 204
  - myeloproliferative neoplasms
    - ASXL1 mutations, 280–281
    - DNMT3A mutations, 280
    - EZH2 mutations, 281
    - LNK mutations, 284
    - NFE2 mutations, 286
    - PPM1D mutations, 287
    - PTPN11, 285
    - RUNX1 mutations, 285–286
    - SF3B1 mutations, 283–284
    - SRSF2 mutations, 282
    - TET2 mutations, 279
    - TPE53 mutations, 287
    - U2AF1 mutations, 283
    - ZRSR2 mutations, 283
- MPAL, 374
- MPL, 257, 276, 326
- MPL, 272
- MPNs. *See* Myeloproliferative neoplasms
- MPP. *See* Multipotent progenitor
- MRD. *See* Minimal residual disease
- MSI1, 158–159
- MSI2, 158–159, 162, 164
- MTHFD2, 183
- Multiple myeloma (MM)
  - cancer cell biology targeting, 492–493
  - clonal hematopoiesis, 71, 76
  - immunological targeting, 493–497
  - novel therapies
    - classification of therapies, 488–489
    - incorporation into combination therapies, 489–490
    - plasma cell biology targeting, 490–492
  - overview, 487–488
  - prospects for treatment, 497
- Multipotent progenitor (MPP)
  - lineage bias and reprogramming during emergency hematopoiesis, 8
  - progeny, 3
- Mxl, 209
- MYB, 263
- MYB, 152–153, 161, 336, 343
- MYBBP1A, 164

## Index

- MYC, 152, 154–155, 159, 176, 178, 184–185, 187  
MYC, 52, 54, 153, 162, 232–233, 336, 342–343, 448, 452, 492
- Mycosis fungoides (MF), genetics, 56–57, 476
- MYD88, 53, 239, 242, 389, 451–453
- Myeloproliferative neoplasms (MPNs)
- ASXL1 mutations, 280–281
  - CBL mutations, 284–285
  - common mutations, 273–275
  - DNMT3A mutations, 279–280
  - EZH2 mutations, 281
  - IDH1/2 mutations, 279
  - JAK-STAT signaling pathway mutations, 272, 276
  - KRAS mutations, 285
  - LNK mutations, 284
  - NFE2 mutations, 286
  - NRAS mutations, 285
  - overview, 271–272
  - PPM1D mutations, 287
  - prospects for study, 289
  - RUNX1 mutations, 285–286
  - SF3B1 mutations, 283–284
  - SRSF2 mutations, 282
  - TET2 mutations
    - clinical studies, 277–279
    - mouse models, 279
    - overview, 276–277
  - therapy, 287–288
  - TPE53 mutations, 286–287
  - U2AF1 mutations, 282–283
  - ZRSR2 mutations, 283
- MYH11, 296–297
- N**
- Natural killer/T-cell lymphoma (NKTCL)
- clinical presentation, 474
  - pathogenesis, 474–475
- NCOA2, 432
- NF1, 303–304, 347, 439, 471
- NF2, 439
- NFE2, 286
- NF- $\kappa$ B, 236, 241–242
- NHL. *See* Non-Hodgkin lymphoma
- Nivolumab, 480
- NKX2.1, 336–337, 342
- NKX2.2, 336, 342
- NKX2.5, 336, 342
- NKTCL. *See* Natural killer/T-cell lymphoma
- Nkx2.3, 206
- NKX3.1, 341
- Non-Hodgkin lymphoma (NHL)
- epidemiology, 35–38
  - genetics, 450–451
  - germinal center B-cell-derived lymphomas, 451–452
  - heterogeneity, 460–461
  - immunodeficiency-related lymphoma, 453–454
  - lymphomagenesis, 448
  - models, 458–460
  - overview, 447–448
  - post-germinal center and marginal zone B-cell-derived lymphomas, 452–453
  - pre-germinal center B-cell-derived lymphomas, 451
  - primary cutaneous B-cell lymphoma, 453
  - treatment
    - chemotherapy, 455–456
    - immunotherapy, 458
    - overview, 454–455
    - targeted therapy, 456–458
- NOTCH1, 176, 337–340, 343, 396, 400, 474
- NOTCH1, 50, 162, 242, 389, 451
- NOTCH2, 243
- NOTCH2, 51, 53
- NOXA, 186
- NPM1, 74–75, 300–301, 305
- NR3C1, 377
- NRAS, 205, 207, 285, 303, 336, 364, 439
- NRF1, 6
- NT5C2, 183
- NTRK1, 432, 435
- NUP214, 299, 342
- NUP98
- Nup98, 206
- NUTM1, 374
- O**
- OGDH, 180
- Oxidative phosphorylation. *See* Metabolism, leukemia/lymphoma
- Oxidative stress
- hematopoietic stem cell DNA damage and functional decline, 5–6
  - leukemia, 183
  - lymphoma, 187
- P**
- P16, 340
- p38 MAPK, 5–6
- Panobinostat, 488
- PARI, 368
- PAX5, 178, 235
- PAX5, 364, 368, 372, 375
- PBX1, 368
- PCYT1A, 187
- PD-1, 479–480

- PDGFRA*, 369  
*PDGFRB*, 369  
PDH, 180  
PD-L1, 474  
*PDL1*, 55  
*PDL2*, 55  
Pembrolizumab, 480  
Peripheral T-cell lymphoma (PTCL)  
    not otherwise specified, 471–472  
    overview, 154, 467  
*PHF6*, 336, 345  
PI3K, 403, 431  
*PICALM*, 342  
*PIGA*, 74  
*PIK3CA*, 372, 431  
*PIK3CD*, 431  
*PIMI1*, 52, 452  
*PLCG1*, 56, 476  
PMBL. *See* Primary mediastinal large B-cell lymphoma  
Pomalidomide, 488  
*POT1*, 389  
PP2A, 187  
PPM1D, 11  
*PPM1D*, 70, 76, 287  
Pralatrexate, 477–478  
PRC1, 280, 306  
PRC2, 120, 132, 281, 306  
*PRDM1*, 130, 237, 239, 241  
PRIMA-1, 308  
Primary cutaneous B-cell lymphoma (CBCL), 453  
Primary mediastinal large B-cell lymphoma  
    (PMBL), genetics, 55  
*PRPF40B*, 282  
*PRPF8*, 307  
PSEN1, 339  
PTCL. *See* Peripheral T-cell lymphoma  
*PTD*, 299  
PTEN, 152, 178, 181  
*PTEN*, 339, 346  
PTPMT1, 6  
*PTPN11*, 285, 303, 364  
PU.1, 8, 343  
PUMA, 186
- R**
- RAD21*, 121, 214, 329  
*RAD21*, 307  
RAF isoforms, 430–431  
RAF1, 425, 439  
RAS, isoforms, 178, 431  
*RBI*, 328, 340, 364  
RBM15, 152–154, 328  
RBM39, 151–152, 160–161, 164
- RBPs. *See* RNA-binding proteins  
RDD. *See* Rosai–Dorfman–Destombes disease  
RELA, 241  
RELB, 241  
*RET*, 435  
*RHOA*, 470–471, 474, 476  
Richter’s transformation. *See* Chronic lymphocytic  
    leukemia  
Rituximab, 398, 455–456  
*RLTPR*, 476  
RNA-binding proteins (RBPs). *See also specific proteins*  
    noncoding RNA regulators in leukemia/lymphoma  
        LIN28A, 154–155  
        LIN28B, 154–155  
        MYC, 152  
    overview in leukemia/lymphoma, 145–150  
    RNA modifier regulators in leukemia/lymphoma  
        METTL3, 152–153  
        RBM15, 153–154  
    RNA stability and translation regulators in  
        leukemia/lymphoma  
        eIF4e, 155–157  
        hnRNPk, 159–160  
        HuR, 155–156  
        insulin-like growth factor binding proteins,  
            157–158  
        MSI2, 158–159  
        SYNCRIP, 159  
    splicing regulators in leukemia/lymphoma  
        RBM39, 151–152  
        SF3B1, 150–151  
        SRSF2, 150–151  
        U2AF1, 150–151  
    therapeutic targeting in leukemia/lymphoma  
        cap-dependent translation, 161–162  
        LIN28, 161  
        MSI2, 162  
        prospects, 162–164  
        RBM39, 160–161  
        spliceosome, 160  
ROR-1, 392  
RORA, 263  
Rosai–Dorfman–Destombes disease (RDD)  
    cellular origins, 432–433  
    clinical presentation, 430  
    immunophenotypic features, 429  
    treatment, 433–435  
*RPL10*, 348  
*RRAGC*, 234, 238  
*RUN2*, 336  
*RUNX1*, 264, 282  
*RUNX1*, 255, 259–260, 262, 285–286, 296–297, 301,  
    308, 321, 323–325, 344, 367–369  
*RUNXIT1*, 296–297

## Index

### S

S1PR2, 240  
SAHM1, 340  
SALL1, 374  
SCD1, 182  
SEH2B, 242  
SESTRINI, 186  
SET, 342  
SETD1B, 471  
SETD2, 364, 377  
SETD2, 475  
Sézary syndrome, genetics, 56–57, 476  
SF1, 282  
SF3A1, 282  
SF3B1, 150–151, 160, 282  
SF3B1, 242–243, 283–284, 307, 389  
SGK1, 452  
SH2B3, 369  
SHMT, 187  
SIRT7, 6  
SLAMF7, 494  
SLC1A3, 183  
SMARCA2, 372  
SMARCC1, 476  
SMC1A, 121, 214  
SMC3, 121, 214  
SMRT, 236  
SMZL. *See* Splenic marginal zone lymphoma  
SNHG5, 348  
SOCS1, 55  
SOX4, 263  
SOX11, 50  
SOX11, 451  
SPEN, 452  
SPI1, 264  
SPI1, 336, 343  
Splenic marginal zone lymphoma (SMZL),  
    genetics, 51  
SREBP1, 187  
SRSF2, 150–151  
SRSF2, 214, 257, 282, 287, 307, 308  
STAG1, 121, 307  
STAG2, 121, 214, 307, 329  
STAT3, 159  
STAT3, 472, 475–476  
STAT5, 14  
STAT5B, 56, 347, 475–476  
STMN1, 343  
SUZ12, 120, 336, 345  
SYK, 456  
SYNCRIP, 159  
SYNCRIP, 348

### T

TAF15, 372  
TAL1, 336, 341, 343  
TAL2, 341  
T-ALL. *See* T-cell acute lymphoblastic leukemia  
Tax, 473  
TBX21, 472  
T-cell acute lymphoblastic leukemia (T-ALL)  
    cell cycle disruption, 340–341  
    epigenetic regulator mutations  
        EED, 345  
        EZH2, 345  
        KDM6A, 345  
    overview, 344–345  
        PHF6, 345  
        SUZ12, 345  
    heterogeneity, 336–337  
NOTCH1  
    activation, 337–338  
    oncogenetic pathways and effector  
        mechanisms, 338  
    therapeutic targeting, 338–340  
overview, 335–336  
ribosomal protein mutations, 347–348  
signaling pathway oncogenic activation  
    ABL1 fusion genes, 347  
    IL7 receptor, 346  
    JAK-STAT, 346–347  
    PI3K-AKT, 346  
    RAS-MAPK, 347  
transcription factors  
    oncogenes  
        homeobox transcription factors, 342  
        MYB, 343  
        MYC, 342–343  
        overview, 341–342  
        SPI1, 343  
    tumor suppressor genes  
        BCL11B, 344  
        ETV6, 343  
        GATA3, 344  
        LEF1, 344  
        RUNX1, 344  
        WT1, 344  
T-cell lymphoma. *See also specific lymphomas*  
    classification of mature lymphomas, 468  
    treatment of mature lymphomas, 476–480  
T-cell prolymphocytic leukemia (T-PLL), genetics, 56  
T-cell receptor (TCR), sequencing, 57–58  
TCF3, 232  
TCF3, 54, 368–369  
TCF7, 343  
TCL1, 243

- TCLIA*, 56  
*TCLIB*, 56  
TCR. *See* T-cell receptor  
*TCRA*, 342  
*TCRB*, 343  
*TERT*, 77  
*TET2*, 56, 70, 74–75, 77–78, 117, 119, 121, 128–130, 211–212, 237, 255, 260, 276–279, 305, 469–471, 476  
*TET2*, 7, 11, 13–14, 184  
*TGFB1*, 437  
TIM-3, acute myeloid leukemia therapeutic targeting, 93, 100–101  
*TKD*, 302  
*TLX1*, 336–337, 342–343, 347  
*TLX3*, 336–337, 342–344, 347  
TMD. *See* Transient myeloproliferative disorder  
*TNFAIP3*, 51, 471  
*TNFRSF14*, 52, 234, 237–238  
*TNFRSF17*, 488  
*TNFRSF1B*, 476  
Tofacitinib, 479  
TP53, 214–216, 252  
*TP53*, 11, 13, 49–53, 56, 70, 74, 76, 128, 255, 299–300, 319, 364, 375, 451–452, 471  
*TPE53*, 286–287  
TPEN, 161  
T-PLL. *See* T-cell prolymphocytic leukemia  
*TRAF3*, 241, 471  
Transient myeloproliferative disorder (TMD)  
    clinical and biological features, 324–325  
    transforming mutation acquisition, 325–326  
*TRIB2*, 341  
*TYK2*, 56
- U**
- U2AF1*, 150–151, 160, 283  
*U2AF1*, 214, 282–283, 307  
*U2AF2*, 282–283  
*U2AF2*, 307  
*UTX*, 213
- V**
- VAV1*, 471  
Vemurafenib, resistance mechanisms, 439  
Venetoclax, 183  
Vitamin C, clonal hematopoiesis intervention, 77–78  
*VWE*, 8
- W**
- WHSC1*, 364, 368  
Wnt, 13  
*WT1*, 342, 344  
*WTAR*, 152–153
- X**
- Xfp521*, 206  
*XPO1*, 389
- Y**
- YAP1*, 374  
*YTHDF2*, 153  
*YTHDF2*, 471
- Z**
- ZAP70*, 471  
*ZEB1*, 56  
*ZESR2*, 282  
*ZNF362*, 372  
*ZNF374*, 368  
*ZNF384*, 371–372, 374  
*ZNF618*, 374  
*ZRSR2*, 283, 307